A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab

Trial Profile

A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Bendamustine (Primary) ; Antineoplastics
  • Indications B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ROBIN
  • Sponsors Mundipharma International
  • Most Recent Events

    • 25 Apr 2018 Planned End Date changed from 31 Oct 2018 to 31 Dec 2018.
    • 25 Apr 2018 Planned primary completion date changed from 31 Oct 2018 to 31 Dec 2018.
    • 20 Jul 2017 Planned End Date changed from 1 Nov 2017 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top